Transcatheter mitral valve therapy: The event horizon Vinay Badhwar, MD, Vinod H. Thourani, MD, Gorav Ailawadi, MD, Michael Mack, MD The Journal of Thoracic and Cardiovascular Surgery Volume 152, Issue 2, Pages 330-336 (August 2016) DOI: 10.1016/j.jtcvs.2016.03.049 Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions
Figure 1 Examples of current TMVR devices under active clinical investigation. A, The Tendyne (Abbott Vascular, Santa Clara, Calif). B, The CardiaQ Valve (Edwards Lifesciences, Irvine, Calif). C, The Tiara Valve (Neovasc, Richmond, BC). D, The Twelve Valve (Medtronic Inc, Minneapolis, Minn). The Journal of Thoracic and Cardiovascular Surgery 2016 152, 330-336DOI: (10.1016/j.jtcvs.2016.03.049) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions
The event horizon for transcatheter mitral therapy to enter clinical practice is upon us. The Journal of Thoracic and Cardiovascular Surgery 2016 152, 330-336DOI: (10.1016/j.jtcvs.2016.03.049) Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions